"Propranolol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
| Descriptor ID |
D011433
|
| MeSH Number(s) |
D02.033.100.624.698.711 D02.033.755.624.698.711 D02.092.063.624.698.711 D02.455.426.559.847.638.945 D04.615.638.945
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Propranolol".
Below are MeSH descriptors whose meaning is more specific than "Propranolol".
This graph shows the total number of publications written about "Propranolol" by people in this website by year, and whether "Propranolol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 0 | 3 | 3 |
| 1994 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 1 | 1 | 2 |
| 2006 | 0 | 1 | 1 |
| 2007 | 2 | 0 | 2 |
| 2008 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 0 | 1 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Propranolol" by people in Profiles.
-
Friedman Ohana R, Levin S, Hurst R, Rosenblatt MM, Zimmerman K, Machleidt T, Wood KV, Kirkland TA. Streamlined Target Deconvolution Approach Utilizing a Single Photoreactive Chloroalkane Capture Tag. ACS Chem Biol. 2021 02 19; 16(2):404-413.
-
Keller RG, Stevens S, Hochman M. Modern Management of Nasal Hemangiomas. JAMA Facial Plast Surg. 2017 Jul 01; 19(4):327-332.
-
Shukla R, Kramer J, Cao Y, Ying J, Tansel A, Walder A, Advani S, El-Serag HB, Kanwal F. Risk and Predictors of Variceal Bleeding in Cirrhosis Patients Receiving Primary Prophylaxis With Non-Selective Beta-Blockers. Am J Gastroenterol. 2016 12; 111(12):1778-1787.
-
LeCompte MT, Rae L, Kahn SA. A survey of the use of propranolol in burn centers: Who, what, when, why. Burns. 2017 Feb; 43(1):121-126.
-
Keller RG, Patel KG. Evidence-Based Medicine in the Treatment of Infantile Hemangiomas. Facial Plast Surg Clin North Am. 2015 Aug; 23(3):373-92.
-
May CC, Oyler DR, Parli SE, Talley CL. Rectal propranolol controls paroxysmal sympathetic hyperactivity: a case report. Pharmacotherapy. 2015 Apr; 35(4):e27-31.
-
Mallat NS, Wehbe D, Haddad A, Cappellini MD, Marcon A, Koussa S, Abboud MR, Radwan A, Taher AT. Priapism, an emerging complication in ß-thalassemia intermedia patients. Hemoglobin. 2014; 38(5):351-4.
-
Wine Lee L, Goff KL, Lam JM, Low DW, Yan AC, Castelo-Soccio L. Treatment of pediatric pyogenic granulomas using ß-adrenergic receptor antagonists. Pediatr Dermatol. 2014 Mar-Apr; 31(2):203-7.
-
Saladin ME, Gray KM, McRae-Clark AL, Larowe SD, Yeatts SD, Baker NL, Hartwell KJ, Brady KT. A double blind, placebo-controlled study of the effects of post-retrieval propranolol on reconsolidation of memory for craving and cue reactivity in cocaine dependent humans. Psychopharmacology (Berl). 2013 Apr; 226(4):721-37.
-
Cheng G, Kasiganesan H, Baicu CF, Wallenborn JG, Kuppuswamy D, Cooper G. Cytoskeletal role in protection of the failing heart by ß-adrenergic blockade. Am J Physiol Heart Circ Physiol. 2012 Feb 01; 302(3):H675-87.